Limbal Stem-cell Deficiency clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Stem Cell Therapy for Limbal Stem Cell Deficiency

    open to eligible people ages 18 years and up

    This phase I study will collect preliminary information on the activity and safety of cLSC. We will investigate the ability to manufacture and transplant cLSC onto the cornea successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular surface (efficacy) without serious adverse events (safety).

    Los Angeles, California

Our lead scientists for Limbal Stem-cell Deficiency research studies include .

Last updated: